Strong Funding Tubulis has secured significant investment, with a record-breaking €308 million (approximately US$358 million) Series C funding round, indicating strong investor confidence and substantial financial resources to support expansion and new technology development.

Innovative Pipeline The company is actively developing next-generation antibody-drug conjugates (ADCs) and has recently entered clinical development with a program in collaboration with Bristol Myers Squibb, highlighting opportunities to offer partnering, licensing, or co-development services.

Expanding Market Presence Participation in major biotech events like ESMO 2025 and recent news coverage demonstrates growth momentum and increased visibility within oncology and biotech communities, opening doors for strategic collaborations and partnerships.

Technological Edge Tubulis’s proprietary technologies for generating uniquely matched protein-drug conjugates position it as a potential customer for advanced biotech tools, manufacturing services, or partners offering innovative solutions to accelerate ADC development.

Leadership & Growth Recent hires, including a new CFO and managing partners, reflect a focus on strengthening leadership and operational capacity, which can translate into expanded sales opportunities through strategic advisories, professional service offerings, and capacity support.